{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-273298","form_type":"8-K/A","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.222600+00:00","generated_at":"2026-06-22T21:51:23.234142+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha grants Astellas options for GAN/Rett programs; $20M upfront + $30M equity raise","bullets":["Astellas gets exclusive options to license TSHA-120 (GAN) and TSHA-102 (Rett) post specified clinical/regulatory milestones.","Upfront payment of $20M from Astellas; $30M private placement of 7.27M shares of common stock at ~$4.13/share.","TSHA-120 Type B end-of-Phase 2 FDA meeting scheduled Dec 13, 2022; update expected mid-Jan 2023.","TSHA-102 preliminary safety/efficacy data for adult cohort now expected H1 2023 (delayed from year-end 2022); female pediatric trial to start H1 2023.","Taysha agrees to change-of-control restrictions during Rett option period; Astellas receives board observer right."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-273298","json":"https://secwatch.observer/filing/0001193125-22-273298.json","markdown":"https://secwatch.observer/filing/0001193125-22-273298.md","text":"https://secwatch.observer/filing/0001193125-22-273298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/d395338d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:51:23.234142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14490d0afb1f574e98b9b62b46e111f834a777b6","claim":"Taysha Gene Therapies, Inc. entered into Option Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (\"Astellas\") valued at $20.0 million (effective 2022-10-21).","evidence_excerpt":"On October 21, 2022 (the “Effective Date”), Taysha Gene Therapies, Inc. (the “Company”) entered into an Option Agreement (the “Option Agreement”) with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (“Astellas”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (\"Astellas\")"},{"label":"Value","value":"$20.0 million"},{"label":"Effective","value":"2022-10-21"}],"fact_type":"material_agreement"},{"claim_id":"f87c11463223b0663ae5be9b94b69d902b7622d6","claim":"Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (\"Astellas\") valued at approximately $30.0 million (effective 2022-10-21).","evidence_excerpt":"On October 21, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Astellas, pursuant to which the Company agreed to issue and sell to Astellas in a private placement (the “Private Placement”) an aggregate of 7,266,342 shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (\"Astellas\")"},{"label":"Value","value":"approximately $30.0 million"},{"label":"Effective","value":"2022-10-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}